146 related articles for article (PubMed ID: 37752418)
1. Hepatocyte-specific HDAC3 ablation promotes hepatocellular carcinoma in females by suppressing Foxa1/2.
Xu Y; Zhu Y; Wu Z; Li S; Shao M; Tao Q; Xu Q; Chen Y; Shu Y; Chen M; Zhou Y; Shi Y
BMC Cancer; 2023 Sep; 23(1):906. PubMed ID: 37752418
[TBL] [Abstract][Full Text] [Related]
2. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer.
Li Z; Tuteja G; Schug J; Kaestner KH
Cell; 2012 Jan; 148(1-2):72-83. PubMed ID: 22265403
[TBL] [Abstract][Full Text] [Related]
3. Trans-acting non-synonymous variant of FOXA1 predisposes to hepatocellular carcinoma through modulating FOXA1-ERα transcriptional program and may have undergone natural selection.
Wang S; Xiang C; Mou L; Yang Y; Zhong R; Wang L; Sun C; Qin Z; Yang J; Qian J; Zhao Y; Wang Y; Pan X; Qie J; Jiang Y; Wang X; Yang Y; Zhou WP; Miao X; He F; Jin L; Wang H
Carcinogenesis; 2020 Apr; 41(2):146-158. PubMed ID: 31400761
[TBL] [Abstract][Full Text] [Related]
4. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
[TBL] [Abstract][Full Text] [Related]
5. Integrative genomic analysis identifies that SERPINA6-rs1998056 regulated by FOXA/ERα is associated with female hepatocellular carcinoma.
Shen N; Gong J; Wang Y; Tian J; Qian J; Zou L; Chen W; Zhu B; Lu X; Zhong R; Guo A; Wang L; Miao X
PLoS One; 2014; 9(9):e107246. PubMed ID: 25198130
[TBL] [Abstract][Full Text] [Related]
6. Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice.
Kong L; Zhou Y; Bu H; Lv T; Shi Y; Yang J
J Exp Clin Cancer Res; 2016 Sep; 35(1):131. PubMed ID: 27589954
[TBL] [Abstract][Full Text] [Related]
7. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.
Ma HY; Yamamoto G; Xu J; Liu X; Karin D; Kim JY; Alexandrov LB; Koyama Y; Nishio T; Benner C; Heinz S; Rosenthal SB; Liang S; Sun M; Karin G; Zhao P; Brodt P; Mckillop IH; Quehenberger O; Dennis E; Saltiel A; Tsukamoto H; Gao B; Karin M; Brenner DA; Kisseleva T
J Hepatol; 2020 May; 72(5):946-959. PubMed ID: 31899206
[TBL] [Abstract][Full Text] [Related]
8. Tumor Necrosis Factor Receptor-Associated Factor 6 Promotes Hepatocarcinogenesis by Interacting With Histone Deacetylase 3 to Enhance c-Myc Gene Expression and Protein Stability.
Wu H; Yang TY; Li Y; Ye WL; Liu F; He XS; Wang JR; Gan WJ; Li XM; Zhang S; Zhao YY; Li JM
Hepatology; 2020 Jan; 71(1):148-163. PubMed ID: 31155734
[TBL] [Abstract][Full Text] [Related]
9. miR-22 promotes HBV-related hepatocellular carcinoma development in males.
Jiang R; Deng L; Zhao L; Li X; Zhang F; Xia Y; Gao Y; Wang X; Sun B
Clin Cancer Res; 2011 Sep; 17(17):5593-603. PubMed ID: 21750200
[TBL] [Abstract][Full Text] [Related]
10. Estrogen Activation of G-Protein-Coupled Estrogen Receptor 1 Regulates Phosphoinositide 3-Kinase and mTOR Signaling to Promote Liver Growth in Zebrafish and Proliferation of Human Hepatocytes.
Chaturantabut S; Shwartz A; Evason KJ; Cox AG; Labella K; Schepers AG; Yang S; Acuña M; Houvras Y; Mancio-Silva L; Romano S; Gorelick DA; Cohen DE; Zon LI; Bhatia SN; North TE; Goessling W
Gastroenterology; 2019 May; 156(6):1788-1804.e13. PubMed ID: 30641053
[TBL] [Abstract][Full Text] [Related]
11. Sex hormone-binding globulin suppresses NAFLD-triggered hepatocarcinogenesis after menopause.
Lee SR; Lee YH; Yang H; Lee HW; Lee GS; An BS; Jeung EB; Park BK; Hong EJ
Carcinogenesis; 2019 Aug; 40(8):1031-1041. PubMed ID: 31168625
[TBL] [Abstract][Full Text] [Related]
12. Interplay of estrogen receptors and FOXA factors in the liver cancer.
Zhao Y; Li Z
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3(0 3):334-9. PubMed ID: 25661537
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microRNA-21 expression.
Li CH; Xu F; Chow S; Feng L; Yin D; Ng TB; Chen Y
Eur J Cancer; 2014 Oct; 50(15):2560-9. PubMed ID: 25087183
[TBL] [Abstract][Full Text] [Related]
14. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis.
He F; Zhang P; Liu J; Wang R; Kaufman RJ; Yaden BC; Karin M
J Hepatol; 2023 Aug; 79(2):362-377. PubMed ID: 36996941
[TBL] [Abstract][Full Text] [Related]
15. Foxa1 and Foxa2 regulate bile duct development in mice.
Li Z; White P; Tuteja G; Rubins N; Sackett S; Kaestner KH
J Clin Invest; 2009 Jun; 119(6):1537-45. PubMed ID: 19436110
[TBL] [Abstract][Full Text] [Related]
16. FOXA1 inhibits hepatocellular carcinoma progression by suppressing PIK3R1 expression in male patients.
He S; Zhang J; Zhang W; Chen F; Luo R
J Exp Clin Cancer Res; 2017 Dec; 36(1):175. PubMed ID: 29208003
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase 3 promotes liver regeneration and liver cancer cells proliferation through signal transducer and activator of transcription 3 signaling pathway.
Lu XF; Cao XY; Zhu YJ; Wu ZR; Zhuang X; Shao MY; Xu Q; Zhou YJ; Ji HJ; Lu QR; Shi YJ; Zeng Y; Bu H
Cell Death Dis; 2018 Mar; 9(3):398. PubMed ID: 29540666
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis.
Bonnin M; Fares N; Testoni B; Estornes Y; Weber K; Vanbervliet B; Lefrançois L; Garcia A; Kfoury A; Pez F; Coste I; Saintigny P; Viari A; Lang K; Guey B; Hervieu V; Bancel B; Bartoch B; Durantel D; Renno T; Merle P; Lebecque S
J Hepatol; 2019 Oct; 71(4):763-772. PubMed ID: 31220470
[TBL] [Abstract][Full Text] [Related]
19. G-Protein-Coupled Estrogen Receptor 1 Promotes Gender Disparities in Hepatocellular Carcinoma via Modulation of SIN1 and mTOR Complex 2 Activity.
Feng G; Cai J; Huang Y; Zhu X; Gong B; Yang Z; Yan C; Hu Z; Yang L; Wang Z
Mol Cancer Res; 2020 Dec; 18(12):1863-1875. PubMed ID: 32873626
[TBL] [Abstract][Full Text] [Related]
20. Tristetraprolin Promotes Hepatic Inflammation and Tumor Initiation but Restrains Cancer Progression to Malignancy.
Dolicka D; Sobolewski C; Gjorgjieva M; Correia de Sousa M; Berthou F; De Vito C; Colin DJ; Bejuy O; Fournier M; Maeder C; Blackshear PJ; Rubbia-Brandt L; Foti M
Cell Mol Gastroenterol Hepatol; 2021; 11(2):597-621. PubMed ID: 32987153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
